drugset / Trial / NCT00005982

506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma

NCT00005982

Phase 2 Terminated 35 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory cutaneous T-cell lymphoma

Timeline

Start
2000-04
Primary completion
2004-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelarabine Small molecule Intravenous